https://www.selleckchem.com/products/eht-1864.html No rat in the KXA group regained a paw withdrawal reflex during alfaxalone administration, whereas 3 of the 12 rats (25%) in the KX group that reached a surgical plane of anesthesia exited that plane within the 35-min timeframe. Neither heart rate, respiratory rate, SpO₂, body temperature, nor time to standing differed between KXA and KX groups; and there were no sex-associated differences in anesthesia response. These results indicate that alfaxalone (10 mg/kg/h IV) delivered through continuous rate infusion, in combination with ketamine and xylazine, provides a safe, prolonged, and reliable surgical plane of anesthesia in rats.Acute myeloid leukemia (AML) with NPM1 mutation is a disease driving genetic alteration with good prognosis. Although it has been suggested that NPM1 mutation induces chemo-sensitivity in leukemic cells, the underlying cause for the better survival of NPM1 mutated patients is still not clear. Mutant NPM1 AML has a unique microRNA and their target gene (mRNA) signature compared to wildtype NPM1. Dynamic regulation of miRNA-mRNA has been reported to influence the prognostic outcome. In the present study, in-silico expression data of miRNA and mRNA in AML patients was retrieved from genome data commons and differentially expressed miRNA and mRNA among NPM1 mutated (n=21) and NPM1 wildtype (n=162) cases were identified to establish a dynamic association at molecular level. In-vitro experiments using high throughput RNA sequencing were performed on human AML cells carrying NPM1 mutated and wildtype allele. The comparison of in-vitro transcriptomics data with in-silico miRNA-mRNA expression network data revealed down regulation of SMC1A. On establishing miRNA-mRNA interactive pairs it has been observed that hsa-mir-215-5p (LogFC 0.957; p=0.0189) is involved in the downregulation of SMC1A (LogFC -0.481; p=0.0464) in NPM1 mutated AML. We demonstrated that transient expression of NPM1 mutation upregu